Beyond Pharmaceuticals: Fit-for-Purpose New Approach Methodologies for Environmental Cardiotoxicity Testing

被引:9
|
作者
Daley, Mark C. [1 ,2 ]
Mende, Ulrike [3 ,4 ]
Choi, Bum-Rak [3 ,4 ]
McMullen, Patrick D. [5 ]
Coulombe, Kareen L. K. [1 ,2 ,6 ]
机构
[1] Brown Univ, Sch Engn, Ctr Biomed Engn, Providence, RI USA
[2] Brown Univ, Div Biol & Med, Providence, RI USA
[3] Brown Univ, Rhode Isl Hosp, Cardiovasc Inst, Cardiovasc Res Ctr, Providence, RI USA
[4] Brown Univ, Warren Alpert Med Sch, Providence, RI USA
[5] ScitoVation, Durham, NC USA
[6] Brown Univ, Ctr Biomed Engn, Sch Engn, 184 Hope St,Box D, Providence, RI 02912 USA
基金
美国国家卫生研究院;
关键词
CELL-DERIVED CARDIOMYOCYTES; PLURIPOTENT STEM-CELLS; IN-VIVO EXTRAPOLATION; RISK-ASSESSMENT; DRUG DISCOVERY; VITRO; TOXICITY; SAFETY; HEART; OPPORTUNITIES;
D O I
10.14573/altex.2109131
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Environmental factors play a substantial role in determining cardiovascular health, but data informing the risks presented by environmental toxicants is insufficient. In vitro new approach methodologies (NAMs) offer a promising approach with which to address the limitations of traditional in vivo and in vitro assays for assessing cardiotoxicity. Driven largely by the needs of pharmaceutical toxicity testing, considerable progress in developing NAMs for cardiotoxicity analysis has already been made. As the scientific and regulatory interest in NAMs for environmental chemicals continues to grow, a thorough under-standing of the unique features of environmental cardiotoxicants and their associated cardiotoxicities is needed. Here, we review the key characteristics of as well as important regulatory and biological considerations for fit-for-purpose NAMs for environmental cardiotoxicity. By emphasizing the challenges and opportunities presented by NAMs for environmental car-diotoxicity we hope to accelerate their development, acceptance, and application.
引用
下载
收藏
页码:103 / 116
页数:14
相关论文
共 50 条
  • [21] Biornarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs
    Wagner, J. A.
    Williams, S. A.
    Webster, C. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (01) : 104 - 107
  • [22] A new strategy explores tight oil/gas reservoirs: Fit-for-purpose acid fracturing
    Carpenter, Chris
    Hegazy, G.M.
    Salem, Adel M.
    1600, Society of Petroleum Engineers (SPE) (65): : 100 - 103
  • [23] A Fit-for-Purpose algorithm for Environmental Monitoring based on Maximum likelihood, Support Vector Machine and Random Forest
    Jamali, Ali
    ISPRS TECHNICAL COMMISSION III WG III/2, 10 JOINT WORKSHOP MULTIDISCIPLINARY REMOTE SENSING FOR ENVIRONMENTAL MONITORING, 2019, 42-3 (W7): : 25 - 32
  • [24] Using problem formulation for fit-for-purpose pre-market environmental risk assessments of regulated stressors
    Devos, Yann
    Craig, Wendy
    Devlin, Robert H.
    Ippolito, Alessio
    Leggatt, Rosalind A.
    Romeis, Joerg
    Shaw, Richard
    Svendsen, Claus
    Topping, Christopher J.
    EFSA JOURNAL, 2019, 17
  • [25] Securing Land Rights for All through Fit-for-Purpose Land Administration Approach: The Case of Nepal
    Panday, Uma Shankar
    Chhatkuli, Raja Ram
    Joshi, Janak Raj
    Deuja, Jagat
    Antonio, Danilo
    Enemark, Stig
    LAND, 2021, 10 (07)
  • [26] Universal chromatographic methods and fit for purpose workflows in the research and development of new pharmaceuticals
    Regalado, Erik
    Ahmad, Imad Haidar
    Bennett, Raffeal
    D'Atri, Valentina
    Makarov, Alexey
    Humphrey, Guy
    Mangion, Ian
    Guillarme, Davy
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [27] APPROACH FOR ESTABLISHING NOVEL AND FIT-FOR-PURPOSE CELL VIABILITY METHODS TO SUPPORT CELL MANUFACTURING PROCESS MONITORING
    Sarkar, S.
    Pierce, L.
    Varisco, D.
    Camp, C.
    Hebert, C.
    Lowry, M.
    Evans, Z.
    CYTOTHERAPY, 2024, 26 (06) : S194 - S194
  • [28] Can user testing of a clinical trial patient information sheet make it fit-for-purpose? - a randomized controlled trial
    Peter Knapp
    David K Raynor
    Jonathan Silcock
    Brian Parkinson
    BMC Medicine, 9
  • [29] Results of PD-L1 "Fit-For-Purpose" proficiency testing in Nordic Immunohistochemical Quality Control (NordiQC)
    Kristoffersen, Heidi
    Roge, Rasmus
    Nielsen, Soren
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1374 - 1374
  • [30] Results of PD-L1 "Fit-For-Purpose" proficiency testing in Nordic Immunohistochemical Quality Control (NordiQC)
    Kristoffersen, Heidi
    Roge, Rasmus
    Nielsen, Soren
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1374 - 1374